KLRS
Kalaris
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About KLRS
Kalaris Therapeutics, Inc.
A late-clinical stage allogeneic T-cell immunotherapy company that develops allogeneic, off-the-shelf VST therapies for devastating viral diseases
628 Middlefield Rd., Palo Alto, California 94301
--
Kalaris Therapeutics, Inc., established on August 16, 2013, is a Delaware limited liability company. The company is a leading clinical late-stage cell therapy company developing highly innovative allogeneic T-cell therapies to treat and prevent devastating viral diseases. The Company's innovative and proprietary Virus Specific T Cell (VST) Therapy Platform enables the generation of ready-made VSTs designed to restore immunity in patients with T cell deficiency.
Company Financials
EPS
KLRS has released its 2025 Q1 earnings. EPS was reported at -2.52, versus the expected -1.17, missing expectations. The chart below visualizes how KLRS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
